Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells

Immunology

Volumn 142, Issue 3, 2014, Pages 396-405

  González, Fermín E ^a,b   Ortiz, Carolina ^a   Reyes, Montserrat ^b   Dutzan, Nicolás ^b   Patel, Vyomesh ^c   Pereda, Cristián ^a   Gleisner, Maria A ^a,d   López, Mercedes N ^a,d,e   Gutkind, J Silvio ^c   Salazar Onfray, Flavio ^a,d  

^a Pontificia Universidad Católica de Chile   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d UNIVERSITY OF CHILE   (Chile)

^e HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

CCR7; Dendritic cells; Immunotherapy; Melanoma; Migration; Tumour lysates

Indexed keywords

CHEMOKINE RECEPTOR CCR7; MACROPHAGE INFLAMMATORY PROTEIN 3BETA;

ALLOGENEIC MELANOMA DERIVED CELL LYSATE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CELL LYSATE; CELL MATURATION; CELL MIGRATION; CERVICAL LYMPH NODE; CONTROLLED STUDY; DENDRITIC CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR ANTIGEN PRESENTING CELL;

CCR7; DENDRITIC CELLS; IMMUNOTHERAPY; MELANOMA; MIGRATION; TUMOUR LYSATES;

ANIMALS; CELL EXTRACTS; CELL LINE, TUMOR; CELL MOVEMENT; DENDRITIC CELLS; HUMANS; LYMPH NODES; MALE; MELANOMA; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; RECEPTORS, CCR7;

EID: 84901976373     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12264     Document Type: Article

References (36)

1. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77.
2. Schmitt N, Morita R, Bourdery L, Bentebibel SE, Zurawski SM, Banchereau J, Ueno H. Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity 2009; 31:158-69.
3. Steinman RM, Idoyaga J. Features of the dendritic cell lineage. Immunol Rev 2010; 234:5-17.
4. + dendritic cells for immune T cell areas. Cell 2010; 143:416-29.
5. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90:3245-87.
6. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15:138-47.
7. Svane IM, Soot ML, Buus S, Johnsen HE. Clinical application of dendritic cells in cancer vaccination therapy. APMIS 2003; 111:818-34.
8. Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J, Palucka AK. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci 2003; 987:180-7.
9. Escobar A, Lopez M, Serrano A et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 2005; 142:555-68.
10. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, Qin S, Lanzavecchia A. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998; 28:2760-9.
11. Stein JV, Soriano SF, M'Rini C et al. CCR7-mediated physiological lymphocyte homing involves activation of a tyrosine kinase pathway. Blood 2003; 101:38-44.
12. Willimann K, Legler DF, Loetscher M, Roos RS, Delgado MB, Clark-Lewis I, Baggiolini M, Moser B. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 1998; 28:2025-34.
13. Luther SA, Tang HL, Hyman PL, Farr AG, Cyster JG. Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse. Proc Natl Acad Sci USA 2000; 97:12694-9.
14. Alvarez D, Vollmann EH, von Andrian UH. Mechanisms and consequences of dendritic cell migration. Immunity 2008; 29:325-42.
15. Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 2008; 8:362-71.
16. Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E, Lipp M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99:23-33.
17. Ohl L, Mohaupt M, Czeloth N et al. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 2004; 21:279-88.
18. Gunn MD, Kyuwa S, Tam C, Kakiuchi T, Matsuzawa A, Williams LT, Nakano H. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999; 189:451-60.
19. Krautwald S, Ziegler E, Forster R, Ohl L, Amann K, Kunzendorf U. Ectopic expression of CCL19 impairs alloimmune response in mice. Immunology 2004; 112:301-9.
20. Lin CL, Suri RM, Rahdon RA, Austyn JM, Roake JA. Dendritic cell chemotaxis and transendothelial migration are induced by distinct chemokines and are regulated on maturation. Eur J Immunol 1998; 28:4114-22.
21. Lopez MN, Pereda C, Segal G et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor β-expressing T cells. J Clin Oncol 2009; 27:945-52.
22. Mendoza-Naranjo A, Saez PJ, Johansson CC et al. Functional gap junctions facilitate melanoma antigen transfer and cross-presentation between human dendritic cells. J Immunol 2007; 178:6949-57.
23. Aguilera R, Saffie C, Tittarelli A et al. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res 2011; 17:2474-83.
24. Tittarelli A, González FE, Pereda C et al. Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients. Cancer Immunol Immunother 2012; 61:2067-77.
25. Berges C, Naujokat C, Tinapp S, Wieczorek H, Hoh A, Sadeghi M, Opelz G, Daniel V. A cell line model for the differentiation of human dendritic cells. Biochem Biophys Res Commun 2005; 333:896-907.
26. Scandella E, Men Y, Legler DF, Gillessen S, Prikler L, Ludewig B, Groettrup M. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood 2004; 103:1595-601.
27. Sanchez-Sanchez N, Riol-Blanco L, Rodriguez-Fernandez JL. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J Immunol 2006; 176:5153-9.
28. Duran-Aniotz C, Segal G, Salazar L et al. The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses. Cancer Immunol Immunother 2012; 62:761-72.
29. Chen Z, Zhang K, Zhang X, Yuan XH, Yuan Z, Jin L, Xiong M. Comparison of gene expression between metastatic derivatives and their poorly metastatic parental cells implicates crucial tumor-environment interaction in metastasis of head and neck squamous cell carcinoma. Clin Exp Metastasis 2003; 20:335-42.
30. Zhang X, Liu Y, Gilcrease MZ, Yuan XH, Clayman GL, Adler-Storthz K, Chen Z. A lymph node metastatic mouse model reveals alterations of metastasis-related gene expression in metastatic human oral carcinoma sublines selected from a poorly metastatic parental cell line. Cancer 2002; 95:1663-72.
31. Sacks PG. Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck. Cancer Metastasis Rev 1996; 15:27-51.
32. Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol 2008; 84:319-25.
33. Salcedo M, Bercovici N, Taylor R et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 2006; 55:819-29.
34. Geiger JD, Hutchinson RJ, Hohenkirk LF et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61:8513-9.
35. Mendoza-Naranjo A, Bouma G, Pereda C et al. Functional gap junctions accumulate at the immunological synapse and contribute to T cell activation. J Immunol 2011; 187:3121-32.
36. Reyes D, Salazar L, Espinoza E et al. Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. Br J Cancer 2013; 109:1488-97.